Marquette Asset Management LLC Makes New Investment in IMARA Inc. (NASDAQ:IMRA)

Marquette Asset Management LLC purchased a new position in IMARA Inc. (NASDAQ:IMRAGet Rating) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 78,579 shares of the company’s stock, valued at approximately $96,000.

Several other hedge funds and other institutional investors have also modified their holdings of IMRA. Woodline Partners LP lifted its position in IMARA by 252.9% during the 1st quarter. Woodline Partners LP now owns 1,025,017 shares of the company’s stock worth $1,927,000 after acquiring an additional 734,581 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in IMARA by 273.5% during the 1st quarter. Bank of New York Mellon Corp now owns 69,692 shares of the company’s stock worth $131,000 after purchasing an additional 51,031 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of IMARA by 2.5% in the 1st quarter. Renaissance Technologies LLC now owns 450,500 shares of the company’s stock valued at $847,000 after acquiring an additional 10,900 shares during the last quarter. 59.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of IMARA in a report on Friday, June 10th.

IMARA Trading Down 3.0 %

Shares of IMARA stock traded down $0.07 on Friday, reaching $2.25. 330,098 shares of the company were exchanged, compared to its average volume of 1,083,344. The stock has a fifty day moving average price of $1.43 and a 200-day moving average price of $1.36. The firm has a market capitalization of $59.15 million, a price-to-earnings ratio of -1.08 and a beta of 1.86. IMARA Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $4.36.

IMARA Profile

(Get Rating)

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia.

Featured Stories

Want to see what other hedge funds are holding IMRA? Visit to get the latest 13F filings and insider trades for IMARA Inc. (NASDAQ:IMRAGet Rating).

Institutional Ownership by Quarter for IMARA (NASDAQ:IMRA)

Receive News & Ratings for IMARA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMARA and related companies with's FREE daily email newsletter.